^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Synergistic effects of alpelisib (PI3K inhibitor) and ribociclib (CDK4/6 inhibitor) combination in preclinical colorectal cancer models.

Published date:
01/17/2023
Excerpt:
We explored the in vitro efficacy of drug combinations Ribociclib (R) and Alpelisib (A) in four CRC cell lines with different mutational status; CACO2 (PIK3CA/KRAS wild-type), LS1034 (KRAS mutated), SNUC4 (PIK3CA mutated) and DLD1 (PIK3CA/KRAS mutated)....Drug combination analysis showed that the combination of R and A has a synergistic anti-proliferative effect in all CRC cell lines tested.
DOI:
10.1200/JCO.2023.41.3_suppl.167